1 Min Read
May 11 (Reuters) - Xencor Inc
* Xencor’s lead drug candidate, xmab5871, receives orphan drug designation from fda for treatment of igg4-related disease Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.